Moira Garraus Oneca
Investigador
Research group
Professional network profiles
Last Publications
- Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy Cancers . 16(9): .
- Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes Cancers . 15(19): .
- Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report Cancers . 15(9): .
Projects
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- SGR 2017_Grup de Recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2017 SGR 01672
- Starting - finishing date:
- 2017 - 2021
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.